4.6 Article

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

Related references

Note: Only part of the references are listed.
Article Allergy

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes

Cristina Teodosio et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

Article Pathology

Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis

Christian Baumgartner et al.

AMERICAN JOURNAL OF PATHOLOGY (2009)

Article Hematology

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Andres Forero-Torres et al.

BRITISH JOURNAL OF HAEMATOLOGY (2009)

Review Pharmacology & Pharmacy

Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo

B. Hirsch et al.

CURRENT DRUG TARGETS (2009)

Article Medicine, General & Internal

Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria

P. Valent et al.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)

Review Hematology

Pathogenesis, clinical features, and treatment advances in mastocytosis

A. Pardanani et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2006)

Review Medicine, Research & Experimental

Systemic mastocytosis

C Akin et al.

ANNUAL REVIEW OF MEDICINE (2004)

Article Hematology

Clinical, genetic, and therapeutic insights into systemic mast cell disease

A Tefferi et al.

CURRENT OPINION IN HEMATOLOGY (2004)

Review Hematology

Diagnosis and treatment of systemic mastocytosis: State of the art

P Valent et al.

BRITISH JOURNAL OF HAEMATOLOGY (2003)